期刊文献+

异基因外周血造血干细胞移植及其联合骨髓移植后造血重建及移植物抗宿主病的比较 被引量:2

Comparison of time of hematopoietic reconstitution and incidence of GVHD between patients after allogeneic PBSCT and PBSCT combined with BMT
原文传递
导出
摘要 通过比较异基因外周血造血干细胞移植(PBSCT)与其联合骨髓移植(BMT)治疗白血病过程中造血重建时间、移植物抗宿主病(GVHD)发生率及生存率,探讨二者联合移植对白血病治疗的影响。回顾性分析2003年1月至2009年1月在郑州大学第一附属医院接受全相合异基因造血干细胞移植的152例患者,其中78例单纯接受外周血造血干细胞移植,74例接受外周血造血干细胞移植联合骨髓移植。预处理方案:152例患者均应用改良Bu/CY方案预处理,环孢素A(CsA)联合甲氨蝶呤(MTX)、吗替麦考酚酯(MMF)预防GVHD,流式细胞仪测定外周及骨髓造血干细胞计数。SPSS17.0统计分析两组患者移植后造血重建时间、GVHD的发生率及2年生存率。结果:1、移植后造血重建:接受外周血造血干细胞移植与联合骨髓移植患者的白细胞及血小板重建时间无显著性差异(血小板>20×109/L时间分别为(14.18±4.713)d和(12.55±6.552)d(P>0.05),中性粒细胞>0.5×109/L的时间分别为(12.08±3.586)d和(11.64±5.540)d(P>0.05);2、GVHD:接受PBSCT及联合BMT患者Ⅲ度到Ⅳ度急性GVHD(aGVHD)发生率比较有显著性差异(P=0.05)。两者慢性GVHD(cGVHD)发病率有显著性差异(P=0.01);3、2年生存率:接受外周血干细胞移植及其联合骨髓移植患者2年无病生存率和总生存率无显著性差异(P>0.05)。提示,异基因造血干细胞移植与其联合骨髓移植比较造血重建时间及2年生存率无明显差异,但前者GVHD发生率较高,因此外周血造血干细胞移植联合骨髓移植可能减少急性及慢性GVHD的发生。 To explore impacts of treatment for leukemia,by comparing the time of hematopoietic reconstitution,the incidence of GVHD and survival after allogeneic PBSCT and PBSCT combined with BMT.A total of 152 patients received allogeneic hematopoietic stem cell transplantation at the first affiliated hospital of Zhengzhou university from January 2003 to January 2009,of whom 78 received PBSCT,and 74 received PBSCT combined with BMT.Pretreatment schemes: All patients were adopted in modified Bu/CY conditioning regimen,CsA combined with MTX and MMF to prevent GVHD.Flow cytometer was used to count the peripheral blood and bone marrow stem cell.SPSS17.0 analyzed the time of hematopoietic reconstitution,incidence of GVHD and 2-year survival.Results:(1)Hematopoietic reconstitutions after transplantations: There were no significant differences in white blood cells and platelet reconstruction of patients after PBSCT and PBSCT combined with BMT,(Platelets 20×109 / L,time was 14.18±4.713 days and 12.55±6.552 days respectively,P 0.05;The time of neutrophils 0.5×109 / L was 12.08±3.586 days and 11.64±5.540 days respectively,P0.05).(2)GVHD: There was a significant difference incidence of Ⅲ to Ⅳ Grade aGVHD of patients after PBSCT and PBSCT combined with BMT(P=0.05).There was significant difference in incidence of cGVHD between the two groups(P=0.01).(3)2-year survival rate: There were no significant differences in the 2-year disease-free survival rate and total survival in patients after PBSCT and PBSCT combined with BMT.Though there was not significant difference in hematopoietic reconstitution and 2-year survival rates between the patients after PBSCT and PBSCT combined with BMT,but the former had a higher incidence of GVHD.Therefore,PBSCT combined with BMT may reduce the incidence of acute and chronic GVHD.
出处 《现代免疫学》 CAS CSCD 北大核心 2012年第1期52-55,共4页 Current Immunology
关键词 骨髓移植 移植物抗宿主病 白血病 bone marrow transplantation graft-versus-host disease leukaemia
  • 相关文献

参考文献12

  • 1白庆咸,陈协群,王文清,董宝侠,朱华锋,张永清,张涛,乔庆大,王一苇,刘玲莉,李蕊,白燕妮,孙朝阳,石梅,肖锋,李琳,姚暴英.异基因造血干细胞移植治疗白血病的临床研究[J].临床血液学杂志,2004,17(6):321-323. 被引量:4
  • 2Pavletic Z,Bishop M,Tarantolo S,et al.Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies[J].J Clin Oncol,1997,15:1608-1616.
  • 3Bensinger W,Appelbaum F,Rowley S,et al.Factors that influence collection and engraftment of autologous peripheralblood stem cells[J].J Clin Oncol,1995,13,2547-2555.
  • 4Flowers M,Parker P,Johnstonk,et al.Comparison of chro-nic graft-versus-host disease after transplantation of peripher-al blood stem cells versus bone marrow in allogeneic recipi-ents:long-term follow-up of a randomized trial[J].Blood,2002,100:415-419.
  • 5谢新生,万鼎铭,孙慧,孙玲,刘林湘,姜中兴.外周血造血干细胞移植治疗恶性血液病53例[J].癌症,2007,26(4):403-406. 被引量:6
  • 6谢新生,万鼎铭,孙慧,孙玲,刘林湘,王桂菊,姜中兴,陈绍倩,程远东,刘少君,邹典斌.异基因外周血造血干细胞移植联合骨髓移植治疗白血病30例[J].白血病.淋巴瘤,2009,18(11):657-658. 被引量:3
  • 7Dormady SP,Bashayan O,Dougherty R,et al.Immortalized multipotential mesenchymal cells and the hematopoietic mi-croenvironment[J].Hematother Stem Cell Res,2001,10:125-140.
  • 8Noort WA,Kruisselbrink AB,Anker PS,et al.Mesenchy-mal stem cells promote engraftment of human umbilical cord blood-derived CD34+cells in NOD/SCID mice[J].Exp He-matol,2002,30:870-878.
  • 9Bartholomew A,Sturgeon C,Siatskas M,et al.Mesenchy-mal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo[J].Exp Hematol,2002,30:42-48.
  • 10Glucksberg H,Storb R,Fefer A,et al.Clinical manifesta-tions of graft-versus-host disease in human recipients of mar-row from HLA-matched sibling donors[J].Transplantation,1974,18:295-304.

二级参考文献47

  • 1江倩,黄晓军,陈欢,许兰平,刘代红,陈育红,张耀臣,刘开彦,郭乃榄,陆道培.异基因造血干细胞移植后重症胃肠道出血15例分析[J].中华血液学杂志,2005,26(5):277-280. 被引量:10
  • 2谢新生,万鼎铭,孙慧,孙玲,刘林湘,姜中兴.外周血造血干细胞移植治疗恶性血液病53例[J].癌症,2007,26(4):403-406. 被引量:6
  • 3Pavletic Z, Bishop M, Tarantolo S, et al. Hematopoietic recovery after allogeneic btood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol, 1997, 15: 1608-1616.
  • 4Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol, 1995, 13: 2547-2555.
  • 5Flowers M, Parker P, Johnston L, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood, 2002, 100: 415-419.
  • 6Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus -host disease in human recipients of marrow from HLA-matehed sibling donors. Transplantation, 1974, 18: 295-304.
  • 7Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med, 1 980, 69: 204-217.
  • 8Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematology, 2002, 30: 42-48.
  • 9Dominietto A, Raiola A M, van Lint M T, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host-disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol, 2001, 112:219-2
  • 10Singhal S, Powles R, Henslee-Downey P J, et al. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone marrow transplant, 2002, 29:291-296.

共引文献12

同被引文献30

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部